Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Endothelin Receptor Blockade in Heart Failure With Diastolic Dysfunction and Pulmonary Hypertension.

Next Previous
Trial Profile

Endothelin Receptor Blockade in Heart Failure With Diastolic Dysfunction and Pulmonary Hypertension.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 09 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bosentan (Primary)
  • Indications Heart failure; Pulmonary hypertension
  • Focus Therapeutic Use
  • Acronyms BADDHY

Most Recent Events

  • 27 Jun 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
  • 14 Jan 2010 Additional trial lead investigator identified as reported by ClinicalTrials.gov.
  • 14 Jan 2010 Planned end date changed from 1 Apr 2010 to 1 Apr 2011 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top